Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    Watch the webinar.

    thumbnail
    ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Social media image
ICON Plc logo
ICON Plc

Today \@WVCUS, join ICON plc experts for a working group discussion on ‘Vaccine trials: How AI shifts execution from static plans to living systems’. Learn more at 11:40 am: https://ow.ly/9Uk050Yr8VL

20h
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

ICON’s Patient Centred Outcomes team delivered strong progress in 2025. – Over 45 specialists across Europe and North America – Twelve peer‑reviewed papers and two webinars – Methodological depth across COA strategy, psy...

22h
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON’s Patient Centred Outcomes team delivered strong progress in 2025. – Over 45 specialists across Europe and North America – Twelve peer‑reviewed papers and two webinars – Methodological depth across COA strategy, psy...

22h
1
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GM...

31 Mar
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GM...

31 Mar
1
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Scientific rigor continues to shape payer expectations, and #AMCP2026 offers an important forum for advancing those standards. ICON will be at booth \#1412 to discuss approaches to robust evidence generation, real world ...

30 Mar
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Scientific rigor continues to shape payer expectations, and #AMCP2026 offers an important forum for advancing those standards. ICON will be at booth #1412 to discuss approaches to robust evidence generation, real world d...

30 Mar
2
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

At ICON, we believe that the most valuable learning comes from shared experience. Our teams recently came together for a Clinical Research Associate Masterclass led by Hristina Gogova and Loreta Ivanova. The session off...

30 Mar
View post
Social media image
ICON Plc logo
ICON Plc

Many therapeutic areas lack complete head to head data. Our whitepaper outlines how network meta analysis constructs a connected evidence base by integrating direct and indirect comparisons, provided studies share a su...

30 Mar
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Many therapeutic areas lack complete head to head data. Our whitepaper outlines how network meta analysis constructs a connected evidence base by integrating direct and indirect comparisons, provided studies share a su...

30 Mar
2
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Join ICON at World Vaccine Congress 2026 as we share our latest insights in HIV vaccine and therapeutic development. With 30+ HIV studies, 13,800+ participants, and 20+ years of operational experience across 27 African a...

27 Mar
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our fr...

27 Mar
View post
View webpage
  • 1
  • 2
  • 3
  • …
  • 92
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence